GlassScriptPhysician profile
Arthur C Cacacho
NPI 1679970453
$9,481.17
in general payments reported to CMS, 2019-2025
35 companies · $3,488 in 2025
The $3,488 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.64 · 2021: $173 · 2022: $2,370 · 2023: $1,566 · 2024: $1,856 · 2025: $3,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,560 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,560.32 |
| Education | $349.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,709.40 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $809.08 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $733.17 | 2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $639.08 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $591.83 | 2023-2025 | Dupixent |
| Insmed, INC. | $553.76 | 2021-2025 | Arikayce, Brinsupri |
| Olympus Corporation of The Americas | $543.46 | 2022 | |
| Electromed, INC. | $525.37 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $417.51 | 2022-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $394.59 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $382.43 | 2022-2025 | Glassia, Cuvitru |
| Mylan Specialty L.P. | $342.23 | 2022-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $327.81 | 2022-2025 | Acthar |
| Amgen INC. | $236.89 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $194.50 | 2025 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $137.42 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Pulmonx Corporation | $124.28 | 2023-2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $96.30 | 2025 | Ohtuvayre |
| Csl Behring | $68.98 | 2023 | Hizentra |
| United Therapeutics Corporation | $68.47 | 2022-2025 | Tyvaso |
| Pfizer INC. | $66.08 | 2022-2024 | |
| Inspire Medical Systems, INC. | $65.91 | 2024-2025 | Inspire |
| Inogen, INC. | $62.08 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Gilead Sciences, INC. | $48.20 | 2022-2023 | Veklury |
| Merck Sharp & Dohme LLC | $47.65 | 2022-2024 | Gardasil, Gardasil 9, Capvaxive |
| Vifor Pharma, INC. | $46.66 | 2025 | Zemaira, Veltassa |
| Novo Nordisk INC | $42.16 | 2024-2025 | Wegovy, Ozempic |
| Vapotherm INC | $25.96 | 2022 | |
| Boston Scientific Corporation | $24.47 | 2024 | Watchman Flx |
| Ambu INC. | $23.80 | 2024 | |
| Baxter Healthcare | $23.39 | 2024 | Hillrom - Monarch Airway Clearance System |
| Pharming Healthcare, INC. | $23.19 | 2024 | Ruconest |
| Medtronic, INC. | $21.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Cacacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.